AAAAAA
Results:
1-13
|
Results: 13
Authors:
YAMAGUCHI K
FUSE E
TAKASHIMA M
YASUZAWA T
KUWABARA T
KOBAYASHI S
Citation: K. Yamaguchi et al., DEVELOPMENT OF A SENSITIVE LIQUID-CHROMATOGRAPHY ELECTROSPRAY-IONIZATION TANDEM MASS-SPECTROMETRY METHOD FOR THE MEASUREMENT OF 7-CYANOQUINOCARCINOL IN HUMAN PLASMA, Journal of chromatography B. Biomedical sciences and applications, 713(2), 1998, pp. 447-451
Authors:
KURATA N
KURAMITSU T
TANII H
FUSE E
KUWABARA T
KOBAYASHI H
KOBAYASHI S
Citation: N. Kurata et al., DEVELOPMENT OF A HIGHLY SENSITIVE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC METHOD FOR MEASURING AN ANTICANCER DRUG, UCN-01, IN HUMAN PLASMA OR URINE, Journal of chromatography B. Biomedical sciences and applications, 708(1-2), 1998, pp. 223-227
Authors:
FUSE E
TANII H
KURATA N
KUWABARA T
KOBAYASHI S
Citation: E. Fuse et al., ALTERATION OF PHARMACOKINETICS OF A NOVEL ANTICANCER DRUG, UCN-01, INRATS BY HUMAN A1-ACID GLYCOPROTEIN, Annals of oncology, 9, 1998, pp. 427-427
Authors:
SAUSVILLE EA
LUSH RD
HEADLEE D
SMITH AC
FIGG WD
ARBUCK SG
SENDEROWICZ AM
FUSE E
TANII H
KUWABARA T
KOBAYASHI S
Citation: Ea. Sausville et al., CLINICAL-PHARMACOLOGY OF UCN-01 - INITIAL OBSERVATIONS AND COMPARISONTO PRECLINICAL MODELS, Cancer chemotherapy and pharmacology, 42, 1998, pp. 54-59
Authors:
FUSE E
TANII H
KURATA N
KOBAYASHI H
SHIMADA Y
TAMURA T
SASAKI Y
TANIGAWARA Y
LUSH RD
HEADLEE D
FIGG WD
ARBUCK SG
SENDEROWICZ AM
SAUSVILLE EA
AKINAGA S
KUWAHARA A
KOBASASHI S
Citation: E. Fuse et al., UNPREDICTED CLINICAL-PHARMACOLOGY OF UCN-01 CAUSED BY SPECIFIC BINDING TO HUMAN ALPHA(1)-ACID GLYCOPROTEIN, Cancer research, 58(15), 1998, pp. 3248-3253
Authors:
FUSE E
NISHIIE H
KOBAYASHI H
IKEDA S
SAITO H
COVEY J
KOBAYASHI S
Citation: E. Fuse et al., DISPOSITION OF DX-52-1, A NOVEL ANTICANCER AGENT, AFTER INTRAVENOUS ADMINISTRATION TO MICE AND DOGS, European journal of drug metabolism and pharmacokinetics, 22(1), 1997, pp. 53-63
Authors:
AKAMA T
ISHIDA H
SHIDA Y
KIMURA U
GOMI K
SAITO H
FUSE E
KOBAYASHI S
YODA N
KASAI M
Citation: T. Akama et al., DESIGN AND SYNTHESIS OF POTENT ANTITUMOR 5,4'-DIAMINOFLAVONE DERIVATIVES BASED ON METABOLIC CONSIDERATIONS, Journal of medicinal chemistry, 40(12), 1997, pp. 1894-1900
Authors:
NAKAI D
FUSE E
SUZUKI H
INABA M
SUGIYAMA Y
Citation: D. Nakai et al., EVALUATION OF THE EFFICIENCY OF TARGETING OF ANTITUMOR DRUGS - SIMULATION ANALYSIS BASED ON PHARMACOKINETIC PHARMACODYNAMIC CONSIDERATIONS/, Journal of drug targeting., 3(6), 1996, pp. 443-453
Authors:
FUSE E
TAKAI K
OKUNO K
KOBAYASHI S
Citation: E. Fuse et al., HEPATIC EXTRACTION RATIO OF 5-FLUOROURACIL IN RATS - DOSE DEPENDENCE AND EFFECT OF URACIL AND INTERLEUKIN-2, Biochemical pharmacology, 52(4), 1996, pp. 561-568
Authors:
FUSE E
KOBAYASHI T
INABA M
SUGIYAMA Y
Citation: E. Fuse et al., PREDICTION OF THE MAXIMAL TOLERATED DOSE (MTD) AND THERAPEUTIC EFFECTOF ANTICANCER DRUGS IN HUMANS - INTEGRATION OF PHARMACOKINETICS WITH PHARMACODYNAMICS AND TOXICODYNAMICS, Cancer treatment reviews, 21(2), 1995, pp. 133-157
Authors:
FUSE E
KOBAYASHI S
INABA M
Citation: E. Fuse et al., APPLICATION OF PHARMACOKINETICALLY GUIDED DOSE-ESCALATION WITH RESPECT TO CELL-CYCLE PHASE SPECIFICITY (VOL 86, PG 989, 1994), Journal of the National Cancer Institute, 86(14), 1994, pp. 1101-1101
Authors:
FUSE E
KOBAYASHI S
INABA M
SUZUKI H
SUGIYAMA Y
Citation: E. Fuse et al., APPLICATION OF PHARMACOKINETICALLY GUIDED DOSE-ESCALATION WITH RESPECT TO CELL-CYCLE PHASE SPECIFICITY, Journal of the National Cancer Institute, 86(13), 1994, pp. 989-996
Authors:
SUZUKI F
SHIMADA J
SHIOZAKI S
ICHIKAWA S
ISHII A
NAKAMURA J
NONAKA H
KOBAYASHI H
FUSE E
Citation: F. Suzuki et al., ADENOSINE-A1 ANTAGONISTS .3. STRUCTURE-ACTIVITY-RELATIONSHIPS ON AMELIORATION AGAINST SCOPOLAMINE-INDUCED OR N6-((R)-PHENYLISOPROPYL)ADENOSINE-INDUCED COGNITIVE DISTURBANCE, Journal of medicinal chemistry, 36(17), 1993, pp. 2508-2518
Risultati:
1-13
|